10.07.2012 - Evotec has announced a license and collaboration agreement with Janssen Pharmaceuticals on a portfolio of small molecules and biologics.
The subsidiary of Johnson & Johnson targets a novel academic-biotech collaboration called CureBeta built around a portfolio of diabetes treatments in regenerative medicine put together in the lab of Harvard scientist Douglas Melton. The pharma pays a modest upfront of US$8m for the rights but promised to pay US$300m in milestones per programme. J&J receives the global exclusive rights to the programmes, which involve insulin-producing beta cells. Harvard and Evotec agreed to share profits. In the first stage of the collaboration, Harvard, the Howard Hughes Medical Institute and the Germanbiotech Evotec worked on new assays and tools for regenerating beta cells. With the help of J&J's research expertise, the partners hope to make all stages until approval. The appearance of a big pharma completes the alliance that comprised only academic researchers and a biotech company. "We have not only achieved our scientific goals of creating a superior beta cell drug discovery platform and generating a deep pipeline of novel and exciting targets, but we have also established a new model of collaboration between academia and industry that has proven highly efficient and effective in accelerating innovative scientific development," said Dr. Cord Dohrmann, the CSO at Evotec. Elmar Kraus, analyst at DZ Bank said: "Evotec promised and delivered a research and development alliance with one of the big players inthe field in the already huge and growing indication of diabetes. With this, the CureBeta initiative, established in 2011 with the Howard Hughes Medical Institute (HHMI) at Harvard has already paid off." Evotec shares rose 18% at the German Stock Exchange in Frankfurt.
05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.
04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.
01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.
27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.
25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.
21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.